# IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

> **NCT05155254** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **IO Biotech** · enrollment: 407 (actual)

## Conditions studied

- Metastatic Melanoma
- Unresectable Melanoma

## Interventions

- **DRUG:** IO102-IO103
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05155254
- **Lead sponsor:** IO Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-17
- **Primary completion:** 2025-05-30
- **Final completion:** 2027-09
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155254, "IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05155254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*